OneSkin Secures $20 Million: A Leap in Skin Longevity Science
August 9, 2025, 9:35 pm
OneSkin, a pioneer in skin longevity, secured a significant $20 million investment. Prelude Growth Partners led the round. This strategic capital infusion propels OneSkin's mission. The company aims to redefine aging. Its focus is cellular health. OneSkin’s breakthrough science promises a future of healthier, more resilient skin.
This substantial investment marks a pivotal moment. OneSkin, a San Francisco-based firm, now boasts enhanced resources. Prelude Growth Partners, a New York equity powerhouse, provided the capital. The deal concluded last month. It signals strong confidence in OneSkin’s innovative approach.
OneSkin did not actively seek new funds. Prelude Growth Partners initiated contact. The firm saw unique value. This proactive engagement underscores OneSkin’s market position. The investment allowed OneSkin to transition partners. An early-stage investor was replaced. Prelude offers expertise suited for OneSkin’s current growth phase. This reflects Prelude’s keen interest. The skin longevity sector is booming. OneSkin stands out within it.
OneSkin operates at the forefront of biotechnological research. Its core mission targets "skinspan." This concept extends skin health and functionality. The company focuses on the cellular level. It addresses the root causes of aging. Senescent cells are a primary target. These cells accumulate with age. They are often called "zombie cells." They contribute to chronic inflammation. They accelerate collagen degradation. This process leads to visible aging signs. Fine lines, wrinkles, and dullness emerge. OneSkin's scientific method tackles these cellular culprits directly.
OneSkin developed a proprietary peptide: OS-01. This patented compound is central to their technology. OS-01 specifically targets aging cells. It helps clear senescent cells. It enhances skin behavior. It improves skin appearance. This scientific rigor differentiates OneSkin. Their products are not just cosmetic. They are biological interventions. They offer measurable benefits at the cellular level. This provides a new standard for skincare efficacy.
The company offers a robust product line. Offerings include OS-01 FACE, BODY, and EYE. Recently launched products include OS-01 LIP and HAIR. These products span topical applications and supplements. This broad portfolio addresses diverse consumer needs. Each product aims for cellular optimization. They support overall skin health. Prominent figures support OneSkin. Celebrities back its effectiveness. This broadens brand appeal. It amplifies its message of science-driven beauty.
Prelude Growth Partners brings strategic value. The firm invests in founder-led consumer brands. Its portfolio includes many female-founded businesses. These span health, wellness, beauty, and food. This alignment is crucial. OneSkin was founded by female PhD scientists. This shared vision fosters synergy. Prelude's experience in scaling brands will prove invaluable. Their deep market insights support accelerated growth. They help build modern consumer brands.
The $20 million infusion will fuel significant expansion. OneSkin plans to broaden operations across multiple fronts. Research and development efforts will accelerate. This includes exploring new bio-targets. Product innovation will intensify. New formulations may emerge. The company will expand manufacturing capabilities. It will enhance distribution networks. This allows broader market reach. It will also bolster marketing initiatives. Increased consumer awareness will follow. This growth positions OneSkin as a definitive market leader.
The skin longevity market is rapidly expanding. Consumers seek science-backed solutions. They demand proven results. OneSkin meets this demand. Its emphasis on cellular science resonates deeply. The anti-aging sector is evolving. It moves beyond superficial treatments. It focuses on biological health and true skin vitality. This paradigm shift demands innovation. OneSkin leads this change. Its approach aligns with broader healthspan trends. People desire longer, healthier lives. This includes healthier skin.
OneSkin's journey has involved multiple investors. Previous supporters include Selva Ventures and Unilever Ventures. Plus Capital, 2Future, SOSV, Meta Planet, and Able Partners also invested. This history of support underscores its potential. Each investment fueled growth. The latest investment marks a new chapter. It signifies a move from early-stage to growth-focused partnerships. It solidifies its position as a serious player.
This investment validates OneSkin’s scientific platform. It confirms its business model. It reinforces its market leadership. The capital empowers deeper research. It enables broader product accessibility. OneSkin will continue to innovate. It will deliver groundbreaking solutions. These solutions aim for true skin health. They extend vitality. They redefine beauty standards. The company sets a new benchmark. It challenges traditional beauty narratives. The future of skin health looks brighter with OneSkin's advancements. This $20 million deal ensures continued progress. It cements OneSkin's pioneering role.
This substantial investment marks a pivotal moment. OneSkin, a San Francisco-based firm, now boasts enhanced resources. Prelude Growth Partners, a New York equity powerhouse, provided the capital. The deal concluded last month. It signals strong confidence in OneSkin’s innovative approach.
OneSkin did not actively seek new funds. Prelude Growth Partners initiated contact. The firm saw unique value. This proactive engagement underscores OneSkin’s market position. The investment allowed OneSkin to transition partners. An early-stage investor was replaced. Prelude offers expertise suited for OneSkin’s current growth phase. This reflects Prelude’s keen interest. The skin longevity sector is booming. OneSkin stands out within it.
OneSkin operates at the forefront of biotechnological research. Its core mission targets "skinspan." This concept extends skin health and functionality. The company focuses on the cellular level. It addresses the root causes of aging. Senescent cells are a primary target. These cells accumulate with age. They are often called "zombie cells." They contribute to chronic inflammation. They accelerate collagen degradation. This process leads to visible aging signs. Fine lines, wrinkles, and dullness emerge. OneSkin's scientific method tackles these cellular culprits directly.
OneSkin developed a proprietary peptide: OS-01. This patented compound is central to their technology. OS-01 specifically targets aging cells. It helps clear senescent cells. It enhances skin behavior. It improves skin appearance. This scientific rigor differentiates OneSkin. Their products are not just cosmetic. They are biological interventions. They offer measurable benefits at the cellular level. This provides a new standard for skincare efficacy.
The company offers a robust product line. Offerings include OS-01 FACE, BODY, and EYE. Recently launched products include OS-01 LIP and HAIR. These products span topical applications and supplements. This broad portfolio addresses diverse consumer needs. Each product aims for cellular optimization. They support overall skin health. Prominent figures support OneSkin. Celebrities back its effectiveness. This broadens brand appeal. It amplifies its message of science-driven beauty.
Prelude Growth Partners brings strategic value. The firm invests in founder-led consumer brands. Its portfolio includes many female-founded businesses. These span health, wellness, beauty, and food. This alignment is crucial. OneSkin was founded by female PhD scientists. This shared vision fosters synergy. Prelude's experience in scaling brands will prove invaluable. Their deep market insights support accelerated growth. They help build modern consumer brands.
The $20 million infusion will fuel significant expansion. OneSkin plans to broaden operations across multiple fronts. Research and development efforts will accelerate. This includes exploring new bio-targets. Product innovation will intensify. New formulations may emerge. The company will expand manufacturing capabilities. It will enhance distribution networks. This allows broader market reach. It will also bolster marketing initiatives. Increased consumer awareness will follow. This growth positions OneSkin as a definitive market leader.
The skin longevity market is rapidly expanding. Consumers seek science-backed solutions. They demand proven results. OneSkin meets this demand. Its emphasis on cellular science resonates deeply. The anti-aging sector is evolving. It moves beyond superficial treatments. It focuses on biological health and true skin vitality. This paradigm shift demands innovation. OneSkin leads this change. Its approach aligns with broader healthspan trends. People desire longer, healthier lives. This includes healthier skin.
OneSkin's journey has involved multiple investors. Previous supporters include Selva Ventures and Unilever Ventures. Plus Capital, 2Future, SOSV, Meta Planet, and Able Partners also invested. This history of support underscores its potential. Each investment fueled growth. The latest investment marks a new chapter. It signifies a move from early-stage to growth-focused partnerships. It solidifies its position as a serious player.
This investment validates OneSkin’s scientific platform. It confirms its business model. It reinforces its market leadership. The capital empowers deeper research. It enables broader product accessibility. OneSkin will continue to innovate. It will deliver groundbreaking solutions. These solutions aim for true skin health. They extend vitality. They redefine beauty standards. The company sets a new benchmark. It challenges traditional beauty narratives. The future of skin health looks brighter with OneSkin's advancements. This $20 million deal ensures continued progress. It cements OneSkin's pioneering role.